A team led by Princeton researchers has shown that inhibiting vascular cell adhesion molecule-1/integrin alpha4 signaling could prevent bone metastases of breast cancer, thus handing companies with integrin alpha4 inhibitors on the market or in the clinic a potential repurposing opportunity.